Equities

Biosergen AB

Biosergen AB

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)0.300
  • Today's Change-0.008 / -2.60%
  • Shares traded244.31k
  • 1 Year change-53.87%
  • Beta--
Data delayed at least 15 minutes, as of May 15 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Biosergen AB is a Sweden-based biotechnology company. It carries out biopharmaceutical research and development through its Subsidiary Biosergen AS from laboratory facilities in Trondheim, Norway and several other places worldwide. The Company is developing BSG005, a potentially disruptive antifungal drug which has demonstrated safety and potency advantages over competing antifungals. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS, cancer and transplant patients every year. At equal dose levels BSG005 has demonstrated a three-to-fouold potency advantage against the relevant fungal strains compared to the current standard of care, while being completely free of the kidney toxicity hampering other drugs in its class.

  • Revenue in SEK (TTM)0.00
  • Net income in SEK-27.04m
  • Incorporated2021
  • Employees3.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
ViroGates A/S8.98m-19.97m68.28m10.00--3.25--7.60-6.00-6.001.442.080.33440.3163.64573,300.00-74.36-46.58-80.05-52.0977.2077.91-222.40-238.0110.45-19.080.2833---45.0110.98-25.40------
Immunovia AB (publ)1.21m-260.73m69.02m11.00--1.58--56.95-6.06-6.060.02760.96480.007558.2314.96110,181.80-160.93-41.33-194.89-44.24-5,523.76-7,553.76-21,512.13-20,879.292.03--0.1675--37.5536.48-84.09---50.93--
Prolight Diagnostics AB (publ)0.00-135.46m69.97m16.00--0.3651-----0.4074-0.40740.000.3835------0.00--------------------0.00-----------13.84--
Double Bond Phrmcutcl Intrntnl AB (publ)1.37m-17.34m72.74m10.00--12.95--53.08-0.1837-0.18370.01360.05560.1016--18.59137,033.00-128.49-80.90-198.98-106.45-241.22-686.41-1,265.24-1,360.03---217.550.00--10.25135.07-14.36------
Abera Bioscience AB0.00-16.72m73.69m----12.27-----1.24-1.240.000.3910.00-------115.63-79.43-149.06-96.11--------------------13.73------
ExpreS2ion Biotech Holding AB8.80m-91.40m74.13m26.00--1.13--8.42-2.00-2.000.18331.270.0815--9.91338,423.10-84.61-63.54-105.52-75.88-109.74-1.94-1,038.77-524.31----0.0042--43.07-0.156122.94--19.90--
Coegin Pharma AB0.00-27.98m79.13m----6.07-----2.67-2.670.000.64040.00-------125.24-122.02-201.53-154.70-----------170.65--------20.60------
Chosa Oncology AB73.00k-23.94m79.46m----4.17--1,088.46-0.3524-0.35240.00130.26840.003--0.013---96.68-51.96-178.66-61.92-----32,798.63-708.47---97.97-----98.21--28.33------
Dextech Medical AB0.00-4.53m84.30m1.00--2.73-----0.2449-0.24490.001.67-----------28.96---29.94------------0.00------12.89--0.412--
Sprint Bioscience AB68.36m8.77m84.76m36.009.673.439.091.240.12560.12560.97910.35381.58--11.452,441,286.0020.29-71.2243.20-113.7180.0662.7512.83-110.22----0.00--60,725.3022.9999.27---26.02--
Biosergen AB0.00-27.04m85.49m3.00--7.38-----0.4007-0.40070.000.04180.00----0.00-131.31---217.09----------------------32.25------
Opticept Technologies AB9.15m-80.36m90.95m29.00--0.1995--9.95-2.62-2.620.298110.800.0213-0.06382.37315,344.80-18.69-41.76-21.19-46.21125.8862.65-879.63-882.410.6163-14.160.0566---12.9049.1719.80--45.22--
Wntresearch AB0.00-35.82m92.67m2.00--2.28-----0.0919-0.09190.000.0470.00----0.00-89.47-100.71-103.70-123.59------------0.00-------5.65------
Ziccum AB6.64m-20.50m94.39m9.00--7.20--14.23-1.46-1.460.47210.85340.2696--22.01829,375.00-83.29-68.51-106.42-76.47-----308.94-2,598.03----0.0516----75.2025.62---13.45--
AroCell AB (publ)44.79m-56.13m96.29m----0.6288--2.15-0.2437-0.24370.19440.66480.23255.825.63---29.14-29.25-31.00-31.371.88-9.85-125.33-231.195.16--0.00--16.37122.92-0.5494------
Bioextrax AB publ2.06m-21.51m98.88m----4.12--48.07-0.8026-0.80260.07690.69680.0681--124.67---71.17-86.39-82.24-110.8434.95---1,045.50-2,119.90----0.00--420.5124.40-15.21--56.86--
Data as of May 15 2024. Currency figures normalised to Biosergen AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.